Women's Health

New research should give expectant mothers some peace of mind.

Myovant Sciences and Pfizer announces the FDA has approved the therapy for the once-daily treatment of moderate-to-severe endometriosis-associated pain.

This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype. Its approval comes four months ahead of its PDUFA action date.

Oteseconazole treats recurrent vulvovaginal candidiasis in women without reproductive potential.

There are numerous methods of contraception available for adolescents.

Perimenopausal, menopausal, and postmenopausal women experienced a progressive improvement in hair growth, shedding, quality of life, and menopausal symptoms after 12 months with an active nutraceutical supplement.

Perrigo’s HRA Pharma has submitted an application to the FDA for possible future approval of the first-ever OTC birth control pill.

Results suggest the potential of this oral therapy to address the unmet clinical need for long-term medical treatment for endometriosis.

The Department of Health and Human Services (HHS) launched a website Friday which offers women a comprehensive list of reproductive health care resources, services, and information.

The American Medical Association is urging the FDA to approve OTC access to oral contraceptives.

The pipeline includes next-in-class treatments for melanoma, NSCLC, breast cancer, and multiple myeloma.

Prenatal use of the psychoactive drug benzodiazepines is not a major risk factor for altered neurodevelopment in early childhood, despite crossing the human blood-placenta barrier.

A survey saw that of teenagers who sought care in the ED and were prescribed outpatient treatment, fewer than half who received an STI diagnosis filled their prescriptions.

Vitamins and diet can play a role in the prevention and treatment of uterine fibroids, according to a literature review spanning 20 years published in the journal Nutrients.

In June 2021, ibrexafungerp (Brexafemme; Scynexis) became the first drug approved by the U.S. Food and Drug Administration (FDA) in a novel antifungal class in more than 20 years and is now available to treat vulvovaginal candidiasis (VVC).

Pharmacists can improve quality of life for the women they care for by offering advice, education, and other point-of-care services.

Oteseconazole (Vivjoa) reduces the incidence of recurrent vulvovaginal candidiasis.

Data from a cohort of 5000 patients indicates that NSAID use may negatively effect clodronate therapy in older women.

Between 6% and 10% of women diagnosed with vulvovaginal candidiasis are believed to develop a recurrent form of this condition with 3 to 4 or more episodes in a single year.

Ibrexafungerp is a promising novel, well-tolerated and effective oral 1-day treatment for acute vulvovaginal candidiasis.

Apetamin has been promoted worldwide as a weight gain supplement—but what are the dangers of misuse?

While the use of combined oral contraceptives in patients with rheumatoid and autoimmune disorders have focused on safety, a recent narrative review highlighted the efficacy and benefits of these contraceptives in women with RA.

A presentation at the Society for Maternal-Fetal Medicine’s (SMFM) 42nd Annual Pregnancy Meeting explored possible associations with marijuana use and nausea and vomiting in early pregnancy.

An oral concurrent session at SMFM’s 42nd Annual Pregnancy Meeting highlighted an analysis of pregnancy outcomes after optimal prenatal opioid use disorder care.